TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9852985
Drug: Control pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control pneumococcal polysaccharide vaccine
Study: 3141301
Drug: Enoxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin (400 mg tablet)
Study: 3141301
Drug: Ceftriaxone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (250 mg injection)
Study: 21676232
Drug: Conventional Radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Radiotherapy in 28 fractions to a dose of 50.4 Gy and consecutive boost in 8 fractions to a total dose of 66.4 Gy
Study: 16525138
Drug: Entecavir 0.5
Normalized name: entecavir 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.5 mg once daily for a minimum of 52 weeks
Study: 16525138
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg once daily for a minimum of 52 weeks
Study: 14633754
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ropivacaine 0.2% 5 ml h(‐1) for 55 h after infiltration with ropivacaine 0.5% 40 ml.
Study: 14633754
Drug: Systemic analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic analgesia with continuous i.v. infusion of morphine plus ketorolac for 24 h followed by saline infusion for 55 h.
Study: 11602412
Drug: Computer-aided dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-aided dosing
Study: 9580382
Drug: Aripiprazole (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (8 weeks of open‐label treatment)
Study: 26656642
Drug: Donepezil (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (first dose)
Study: 23490304
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Compliance Enhancement Therapy (BBCET)
Study: 19537033
Drug: Ulinastatin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (4 x 10^6 U in 100 ml normal saline infused intravenously for 30 min since skin incision, with additional 2 x 10^6 U infused at a rate of 4-6 x 10^4 U x h(-1) until chest closure)
Study: 19537033
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 ml normal saline without ulinastatin)
Study: 16428534
Drug: J‐Tip with
Approvals — FDA: no, EMA: no, PMDA: no
Description: J‐Tip with 0.25 mL of 1% buffered lidocaine (n = 57)
Study: 16428534
Drug: EMLA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA with 2.5 g (n = 59)
Study: 8269798
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg 2 times/day for 12 weeks
Study: 29911379
Drug: Enoxaparin (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (once daily subcutaneous injections)
Study: 26237831
Drug: Auricular pressing
Normalized name: LEMON OIL, COLD PRESSED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular pressing treatment using Semen Vaccariae on auricular points CO10, LO5, TF4, CO15, CO12, and CO13 for three treatment courses
Study: 18343739
Drug: Second-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy and/or crossover between first-line treatment arms
Study: 16911696
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin K3 (n = 23); administered by i.v. infusion of 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by 20 mg i.m. twice daily for 2 weeks
Study: 12726869
Drug: STEP intervention
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: STEP intervention (exercise counseling and prescription of an exercise training heart rate)
Study: 10985895
Drug: CCC (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCC (100 mg/m² of cisplatin, 300 mg/m² of cyclophosphamide, 300 mg/m² of carboplatin)
Study: 10985895
Drug: CC (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (100 mg/m² of cisplatin, 600 mg/m² of cyclophosphamide)
Study: 9229324
Drug: 48-hour bimonthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 48-hour bimonthly LV5-FU bolus and infusion
Study: 6738143
Drug: Monthly feedback
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly feedback of individual performance ranked with that of peers (group 1)
Study: 26987997
Drug: Budesonide-formoterol Spiromax
Normalized name: budesonide / formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-formoterol Spiromax 160/4.5 mcg
Study: 26987997
Drug: Budesonide-formoterol Turbuhaler
Normalized name: budesonide / formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-formoterol Turbuhaler 200/6 mcg
Study: 24875654
Drug: TIP3-2 combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIP3-2 combined with medication (1-2 mg Estazolam nightly)
Study: 24875654
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only (1-2 mg Estazolam nightly)
Study: 22367659
Drug: Sertindole 16
Normalized name: sertindole 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole 16 mg
Study: 15738315
Drug: Behavioral therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapies for methamphetamine abuse
Study: 12518253
Drug: Insulin aspart,
Normalized name: insulin aspart, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin aspart, 0.05 U/kg-body-weight
Study: 12518253
Drug: Insulin lispro,
Normalized name: Insulin Lispro, 100 units/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin lispro, 0.05 U/kg-body-weight
Study: 9689296
Drug: 7.5% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% aqueous sodium lauryl sulfate solution
Study: 8135026
Drug: Oropharyngeal gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal gentamicin (40 mg, 4 times a day)
Study: 2758972
Drug: Secobarbital 50
Normalized name: secobarbital 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital 50 mg
Study: 2758972
Drug: Secobarbital 200
Normalized name: secobarbital 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital 200 mg
Study: 2758972
Drug: Secobarbital (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital (all doses)
Study: 1102569
Drug: Metiapine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metiapine (maximum dose of 450 mg per day)
Study: 1102569
Drug: Chlorpromazine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (maximum daily dose of 900 mg)
Study: 31721790
Drug: UB0316 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: UB0316 (5 billion CFU each of L. salivarius UBLS22, L. casei UBLC42, L. plantarum UBLP40, L. acidophilus UBLA34, B. breve UBBr01, B. coagulans Unique IS2, and 100 mg fructo-oligosaccharides), twice-a-day for 12 weeks
Study: 23499069
Drug: Trypan blue
Normalized name: Trypan Blue
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trypan blue 0.1% injection (0.2 mL)
Study: 23499069
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution injection (0.2 mL)
Study: 19877219
Drug: Daclizumab, mycophenolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab, mycophenolate mofetil, and tacrolimus (modified therapy group)
Study: 19877219
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and steroids (standard therapy group)
Study: 10735789
Drug: Ketamine 0.94
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.94 mg/mL
Study: 10735789
Drug: Ketamine 1.88
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.88 mg/mL
Study: 10735789
Drug: Ketamine 2.83
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2.83 mg/mL
Study: 10735789
Drug: Propofol (9.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (9.4 mg/mL) with ketamine (0.94-1.88 mg/mL)
Study: 1412652
Drug: Ivermectin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (4 doses at 6-monthly intervals)
Study: 2863777
Drug: Milenperone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milenperone (2 X 5 mg daily for the first 3 weeks, then 2 X 10 mg daily for the following 3 weeks)
Study: 2863777
Drug: Milenperone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milenperone (2 X 10 mg daily)
Study: 22479542
Drug: Recombinant Ad5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Ad5 HIV-1 gag vaccine
Study: 19375704
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 microg, 4-hourly, up to 3 doses)
Study: 19375704
Drug: Intracervical PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical PGE2 gel (2 applications at 6-hour interval)
Study: 2666736
Drug: phenobarbital and
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenobarbital and pyrogenal combination
Study: 785959
Drug: Cyclophosphamide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (3 to 1.5 mg/kg b.wt. for 4 months)
Study: 16621226
Drug: Hydralazine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (5 mg as a slow bolus dose given intravenously, repeated every 20 min up to a maximum of five doses)
Study: 16621226
Drug: Labetalol (20‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (20‐mg intravenous bolus dose followed by 40 mg if not effective within 20 min, followed by 80 mg every 20 min up to a maximum dose of 300 mg)
Study: 11375358
Drug: Miglitol plus
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol plus Metformin
Study: 30697688
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume interscalene block using 5 mL of ropivacaine 0.5% (LVS group)
Study: 30697688
Drug: Infraclavicular-subomohyoid block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infraclavicular-subomohyoid block using 25 mL of ropivacaine 0.5% (ISO group)
Study: 25571679
Drug: CPP‐ACP cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP‐ACP cream (Tooth Mousse, GC Europe N.V., Leuven, Belgium)
Study: 31440799
Drug: 177Lu-PSMA radioligand
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-PSMA radioligand therapy (PSMA-RLT)
Study: 28892656
Drug: rt-PA treatment
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA treatment group
Study: 28892656
Drug: non-rt-PA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-rt-PA treatment group
Study: 15014005
Drug: Ketorolac (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (10 ml of a 0.1% ketorolac rinse solution; n = 38)
Study: 15014005
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 ml of rinse solution; n = 19)
Study: 9326833
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (lithium, carbamazepine, and valproate)
Study: 3979291
Drug: Immunoglobulin administration
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin administration (0.25 g/kg body weight)
Study: 29725828
Drug: iv dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv dexmedetomidine 0.5 mcg/kg
Study: 29725828
Drug: iv lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv lidocaine 2 mg/kg
Study: 23167296
Drug: Standard 3‐day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 3‐day bowel preparation
Study: 18594088
Drug: Collagen meniscus
Normalized name: Sus scrofa meniscus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen meniscus implant
Study: 15964200
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of a commercial red beet juice (RBJ) containing 362.7 mg of betalains
Study: 15964200
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of tap water
Study: 9712921
Drug: Lubeluzole 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 5 mg (loading dose 3.75 mg over 1 h)
Study: 9712921
Drug: Lubeluzole 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 10 mg (loading dose 7.5 mg over 1 h)
Study: 2500688
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg disodium cromoglycate (DSCG) four times daily
Study: 5015036
Drug: L‐alpha‐methyldopahydrazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐alpha‐methyldopahydrazine
Study: 5015036
Drug: Levodopa without
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa without L‐alpha‐methyldopahydrazine
Study: 30982849
Drug: Warfarin (INR-adjusted)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (INR-adjusted)
Study: 29145468
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (scaling and root planing plus oral hygiene instructions, and supportive therapy at 3 and 6 months)
Study: 21478329
Drug: Sliding scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding scale regular insulin
Study: 8803526
Drug: Diprafenone administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprafenone administered with food (100 mg)
Study: 8803526
Drug: Diprafenone administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprafenone administered in fasting state (100 mg)
Study: 8803526
Drug: Slow hydroxylator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow hydroxylator of debrisoquine (100 mg with food)
Study: 1323615
Drug: Stavudine (d4T)
Normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine (d4T) at doses of 0.67, 1.33, 2.67, or 4 mg/kg
Study: 1323615
Drug: Stavudine (d4T)
Normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine (d4T) after chronic dosing
Study: 6387568
Drug: Topical .03%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical .03% sodium flurbiprofen
Study: 18405148
Drug: Sodium Diclofenate
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Diclofenate Slow‐released Tablet
Study: 12800105
Drug: Functional oil
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional oil (FctO) composed of medium chain triacylglycerols (50% of fat), phytosterols (22 mg/kg body weight), and n-3 fatty acids (5% of fat)
Study: 10536550
Drug: Riluzole 100
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole 100 mg
Study: 1809619
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase 250,000 IU followed by intravenous heparin along with conventional treatment
Study: 6406037
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + CT (radiotherapy plus adjuvant chemotherapy with vincristine, streptonigrin, cyclophosphamide and prednisone)
Study: 3901875
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pirbuterol + theophylline + hydroxyzine
Study: 3901875
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pirbuterol + theophylline
Study: 29458404
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (guideline therapy)
Study: 21831167
Drug: Colesevelam co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam co-administered with oral glucose
Study: 18514551
Drug: etoricoxib 30
Normalized name: Etoricoxib 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 30 mg
Study: 18514551
Drug: celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 200 mg
Study: 8876072
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg mizolastine
Study: 6870319
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied tetracycline hydrochloride-containing fluorescent ointments, creams, lotions, and tinctures
Study: 6870319
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied medications
Study: 6870319
Drug: Vehicle of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of the topical preparation
Study: 22820735
Drug: Pedometer intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pedometer intervention with instructions to log use daily for 6 months
Study: 21669577
Drug: Diluted propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted propofol (5 mg/mL)
Study: 21669577
Drug: Undiluted propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undiluted propofol (10 mg/mL)
Study: 16781073
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg, 1800 mg, 2600 mg (titrated over 4 doses)
Study: 15274172
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg/day for the first 4 weeks, then flexibly dosed from 10‐20 mg/day)
Study: 11233387
Drug: Prazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin GITS (Minipress XL, 2.5-5 mg once daily)
Study: 11233387
Drug: Enalapril (Enam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (Enam, 5-10 mg once daily)
Study: 7838619
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids from menhaden oil (100-131 mg/kg/day, mean 112.8)
Study: 7838619
Drug: n-6 fatty
Normalized name: n-6 fatty acids
DrugBank: Omega-6 fatty acids (DB13168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-6 fatty acids from safflower oil (102-132 mg/kg/day, mean 113.3)
Study: 3078906
Drug: Once-a-day administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-a-day administration of 1.5 gm of cefatrizine
Study: 3078906
Drug: Twice-a-day administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day administration of 0.75 gm of cefatrizine
Study: 25946654
Drug: High-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rosuvastatin (20 mg)
Study: 19505293
Drug: Self Determination
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self Determination Theory-based (SDT) exercise on prescription intervention
Study: 19505293
Drug: Standard provision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard provision exercise on prescription
Study: 10853850
Drug: Oral ASA
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ASA challenge (doses 10‐312 mg, cumulative dose 500 mg)
Study: 10853850
Drug: Bronchial L‐lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchial L‐lysine (L) ASA challenge (doses 0.18‐115 mg, cumulative dose 182 mg)
Study: 10853850
Drug: Urinary leukotriene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary leukotriene E4 excretion after both challenges
Study: 9489384
Drug: Ceftibuten (Cedax)
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftibuten (Cedax) administered once a day for five consecutive days starting on the day of surgery
Study: 9489384
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic cover (Control group)
Study: 29768290
Drug: ARB MED
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB MED trial (after taking habitual dose of ARB)
Study: 29768290
Drug: PLAC trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLAC trial (after 48 h of placebo medicine)
Study: 18441333
Drug: Raltegravir 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 1600 mg
Study: 16225411
Drug: Hydroxyethylcellulose (HEC)
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethylcellulose (HEC) placebo formulation
Study: 8880031
Drug: D-ribose (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-ribose (60 mg.kg-1 injected over 5 min)
Study: 3229340
Drug: Zindotrine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zindotrine 300 mg
Study: 3307547
Drug: Zindotrine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zindotrine 200 mg
Study: 24960516
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (50 mg/day)
Study: 23080365
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 (10 mg subcutaneously)
Study: 20202859
Drug: CVVH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVVH treatment (in addition to conventional treatment)
Study: 18215753
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy plus exercise
Study: 16492404
Drug: Levosimendan (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (24 microg kg(‐1) bolus plus 24‐h continuous infusion 0.1 microg kg(‐1) min(‐1))
Study: 16492404
Drug: Dobutamine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (initial dose 5 microg kg(‐1) min(‐1), with maximum dose adjustment)
Study: 137922
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salbutamol (200 mug) and Sch 1000 (40 mug)